Health and Healthcare

BioCryst Pharmaceuticals : BCRX

All BioCryst Pharmaceuticals Articles

77 Articles

Jon C. Ogg | Oct 8, 2014 at 12:20 PM EDT

Ebola Drug Stocks React Wildly to Dallas Patient Death

The sad news that Ebola patient Thomas Eric Duncan has died in a Dallas hospital now raises fears that Ebola…

Chris Lange | Oct 6, 2014 at 2:05 PM EDT

Reality Sets in for Ebola Drug Hopefuls

Tekmira Pharmaceuticals downgrade also drags down Sarepta Therapeutics and BioCryst Pharmaceuticals.

Jon C. Ogg | Oct 1, 2014 at 9:55 AM EDT

Major Fallout Stocks After Confirmed Ebola Case in United States

With the CDC not releasing enough data on the patient, there could be an opportunity for traders on both sides…

Jon C. Ogg | Sep 30, 2014 at 5:16 PM EDT

Reaction to Confirmed Ebola Case in U.S. — UPDATED

News has hit of the first confirmed Ebola case in the United States. Companies involved in potential drugs for Ebola…

Lee Jackson | Aug 11, 2014 at 9:34 AM EDT

New Analyst Biotech Stocks to Buy With Gigantic Implied Upside

ThinkstockAfter being absolutely rocked back in the spring, the biotech sector has bounced back smartly. Even a bubble comment from…

Jon C. Ogg | Aug 8, 2014 at 8:34 AM EDT

Top Analyst Upgrades and Downgrades: Zynga, Barrick, Allergan, BioCryst, Mylan, NVIDIA and More

Jon OggStocks turned green on Friday morning on hopes out of Russia, but the markets have remained at risk. Now…

Jon C. Ogg | Aug 4, 2014 at 11:40 AM EDT

Should Investors Really Be Chasing Potential Ebola Treatments?

ThinkstockThe world is dealing with Ebola outbreaks and scares again. We are also in the midst of debates as to…

Jon C. Ogg | Jun 23, 2014 at 8:45 AM EDT

Top Analyst Upgrades and Downgrades: AMD, Dish Network, Facebook, Nordstrom, SunPower and More

These are the top Wall Street analyst upgrades, downgrades and initiations for Monday, June 23, 2014. They include AMD, Dish…

Jon C. Ogg | Jun 10, 2014 at 8:20 AM EDT

After Idenix: The Next Four Biotech Buyout Candidates

Here are the four top biotech names we found that all have hepatitis C drugs in their current pipelines at…

Paul Ausick | May 27, 2014 at 10:50 AM EDT

BioCryst Crushes It on Rare Immune Disorder Drug Trial

BioCryst Pharmaceuticals broke higher Tuesday morning, following the company's announcement that its oral drug for hereditary angioedema met objectives established…

Jon C. Ogg | Jan 28, 2014 at 8:25 AM EST

Top Analyst Upgrades and Downgrades: Apple, BioCryst, Dow Chemical, Sanmina, Sally Beauty and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Tuesday, January 28, 2014.…

Jon C. Ogg | Jan 27, 2014 at 8:45 AM EST

Top Analyst Upgrades and Downgrades: Cisco, Lululemon, Nokia, Peabody, Xerox and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, January 27, 2014.…

Jon C. Ogg | Nov 12, 2013 at 8:30 AM EST

Top Analyst Upgrades and Downgrades: Twitter, Atmel, Gogo, Hologic, Vodafone and More

Jon OggEarnings season may be winding down and the stock market may be close to all-time highs, but now traders…

Jon C. Ogg | Sep 18, 2013 at 11:40 AM EDT

Analyst Sees Big Risks Lurking in Possible Biotech Buyout

ThinkstockViroPharma Inc. (NASDAQ: VPHM) has become the latest and greatest biotech buyout candidate after a report of it being a…

Jon C. Ogg | Aug 22, 2013 at 8:40 AM EDT

Top Analyst Upgrades and Downgrades: Microsoft, Target, Zynga and More

Jon OggNow that stocks have pulled back and interest rates have risen, investors are looking for more guidance on which…

1 2 3 4 5 6

BioCryst Pharmaceuticals : BCRX

All BioCryst Pharmaceuticals Articles

Ebola Drug Stocks React Wildly to Dallas Patient Death

Reality Sets in for Ebola Drug Hopefuls

Major Fallout Stocks After Confirmed Ebola Case in United States

Reaction to Confirmed Ebola Case in U.S. — UPDATED

New Analyst Biotech Stocks to Buy With Gigantic Implied Upside

Top Analyst Upgrades and Downgrades: Zynga, Barrick, Allergan, BioCryst, Mylan, NVIDIA and More

Should Investors Really Be Chasing Potential Ebola Treatments?

Top Analyst Upgrades and Downgrades: AMD, Dish Network, Facebook, Nordstrom, SunPower and More

After Idenix: The Next Four Biotech Buyout Candidates

BioCryst Crushes It on Rare Immune Disorder Drug Trial

Top Analyst Upgrades and Downgrades: Apple, BioCryst, Dow Chemical, Sanmina, Sally Beauty and More

Top Analyst Upgrades and Downgrades: Cisco, Lululemon, Nokia, Peabody, Xerox and More

Top Analyst Upgrades and Downgrades: Twitter, Atmel, Gogo, Hologic, Vodafone and More

Analyst Sees Big Risks Lurking in Possible Biotech Buyout

Top Analyst Upgrades and Downgrades: Microsoft, Target, Zynga and More

Kevin Warsh Would Be a Hawk at the Fed, but Productivity Boom Could Prevail

Ray Dalio: ‘We’re On the Brink’ of Major Problems Within 2 Years

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

"Did you buy It from the mob?": Dave Ramsey hosts floored by 21-year-old's 30% truck loan

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

“Did you buy It from the mob?”: Dave Ramsey hosts floored by 21-year-old’s 30% truck loan

Kevin Warsh Would Be a Hawk at the Fed, but Productivity Boom Could Prevail

BioCryst Pharmaceuticals : BCRX

All BioCryst Pharmaceuticals Articles

Ebola Drug Stocks React Wildly to Dallas Patient Death

Reality Sets in for Ebola Drug Hopefuls

Major Fallout Stocks After Confirmed Ebola Case in United States

Reaction to Confirmed Ebola Case in U.S. — UPDATED

New Analyst Biotech Stocks to Buy With Gigantic Implied Upside

Top Analyst Upgrades and Downgrades: Zynga, Barrick, Allergan, BioCryst, Mylan, NVIDIA and More

Should Investors Really Be Chasing Potential Ebola Treatments?

Top Analyst Upgrades and Downgrades: AMD, Dish Network, Facebook, Nordstrom, SunPower and More

After Idenix: The Next Four Biotech Buyout Candidates

BioCryst Crushes It on Rare Immune Disorder Drug Trial

Top Analyst Upgrades and Downgrades: Apple, BioCryst, Dow Chemical, Sanmina, Sally Beauty and More

Top Analyst Upgrades and Downgrades: Cisco, Lululemon, Nokia, Peabody, Xerox and More

Top Analyst Upgrades and Downgrades: Twitter, Atmel, Gogo, Hologic, Vodafone and More

Analyst Sees Big Risks Lurking in Possible Biotech Buyout

Top Analyst Upgrades and Downgrades: Microsoft, Target, Zynga and More

Kevin Warsh Would Be a Hawk at the Fed, but Productivity Boom Could Prevail

Ray Dalio: ‘We’re On the Brink’ of Major Problems Within 2 Years

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

Featured Reads

"Did you buy It from the mob?": Dave Ramsey hosts floored by 21-year-old's 30% truck loan

Half of America Still Feels Financially Exposed Despite 8% Jump in Security